AutoGenomics introduces first automated molecular assay for Familial Mediterranean Fever

AutoGenomics, a leader in providing automated, molecular testing solutions, announced today that it has launched a new test for the identification of genetic mutations implicated in the development of Familial Mediterranean Fever (FMF). The INFINITI^® Familial Mediterranean Fever Panel provides simultaneous multiplexed determination of 13 genetic variants common to more than 10 afflicted ethnicities of Mediterranean origin on the automated INFINITI^® Analyzer. FMF is prominently present in the Armenian people, Sephardi Jews, Greeks, Arabs and Turks.

“We are very happy that AutoGenomics has taken the initiative to provide us with such a critical tool while also offering the most comprehensive test panel.”

"We are very excited to introduce the first automated molecular assay for Familial Mediterranean Fever," said Fareed Kureshy, President and CEO of AutoGenomics. "Classical methods for comprehensive FMF testing have always revolved around sequencing, a complicated and time consuming process. Our assay will finally bring FMF testing to a more manageable scale."

"Familial Mediterranean Fever is a very serious problem in affected populations," said Omer Sen, President and CEO of the CDK Group, the distributor of AutoGenomics products in Turkey. "We are very happy that AutoGenomics has taken the initiative to provide us with such a critical tool while also offering the most comprehensive test panel." He further said, "We have launched this novel product successfully at the recently held 9th National Medical Genetics Congress in Istanbul."

The AutoGenomics INFINITI^® Familial Mediterranean Fever Panel is for research use only and not for use in diagnostic procedures.